Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Equity (2022 - 2025)

Historic Return on Equity for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to 0.6%.

  • Amylyx Pharmaceuticals' Return on Equity rose 5400.0% to 0.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.6%, marking a year-over-year increase of 5400.0%. This contributed to the annual value of 1.01% for FY2024, which is 11300.0% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Return on Equity stood at 0.6%, which was up 5400.0% from 1.01% recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Return on Equity's 5-year high stood at 0.12% during Q4 2023, with a 5-year trough of 2.7% in Q1 2022.
  • Over the past 4 years, Amylyx Pharmaceuticals' median Return on Equity value was 0.71% (recorded in 2022), while the average stood at 0.81%.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Return on Equity skyrocketed by 22700bps in 2023 and then crashed by -17800bps in 2024.
  • Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Return on Equity stood at 0.82% in 2022, then soared by 114bps to 0.12% in 2023, then tumbled by -1550bps to 1.67% in 2024, then surged by 64bps to 0.6% in 2025.
  • Its last three reported values are 0.6% in Q3 2025, 1.01% for Q2 2025, and 1.19% during Q1 2025.